Loading…
Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia
Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in the dorsolateral prefrontal cortex (DLPFC), a potential target for treatment development...
Saved in:
| Published in: | NPJ schizophrenia 2022-02, Vol.8 (1), p.2-2, Article 2 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3 |
| container_end_page | 2 |
| container_issue | 1 |
| container_start_page | 2 |
| container_title | NPJ schizophrenia |
| container_volume | 8 |
| creator | Bidzinski, Karolina Kozak Lowe, Darby J. E. Sanches, Marcos Sorkhou, Maryam Boileau, Isabelle Kiang, Michael Blumberger, Daniel M. Remington, Gary Ma, Clement Castle, David J. Rabin, Rachel A. George, Tony P. |
| description | Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in the dorsolateral prefrontal cortex (DLPFC), a potential target for treatment development. We examined the effects of active versus sham high-frequency (20-Hz) repetitive transcranial magnetic stimulation (rTMS) on cannabis use in outpatients with schizophrenia and CUD. Secondary outcomes included cannabis craving/withdrawal, psychiatric symptoms, cognition and tobacco use. Twenty-four outpatients with schizophrenia and CUD were enrolled in a preliminary double-blind, sham-controlled randomized trial. Nineteen participants were randomized to receive active (
n
= 9) or sham (
n
= 10) rTMS (20-Hz) applied bilaterally to the DLPFC 5x/week for 4 weeks. Cannabis use was monitored twice weekly. A cognitive battery was administered pre- and post-treatment. rTMS was safe and well-tolerated with high treatment retention (~90%). Contrast estimates suggested greater reduction in self-reported cannabis use (measured in grams/day) in the active versus sham group (Estimate = 0.33,
p
= 0.21; Cohen’s
d
= 0.72), suggesting a clinically relevant effect of rTMS. A trend toward greater reduction in craving (Estimate = 3.92,
p
= 0.06), and significant reductions in PANSS positive (Estimate = 2.42,
p
= 0.02) and total (Estimate = 5.03,
p
= 0.02) symptom scores were found in the active versus sham group. Active rTMS also improved attention (Estimate = 6.58,
p
|
| doi_str_mv | 10.1038/s41537-022-00210-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_616ddf90cca246e7bfc1efc072f8aad3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_616ddf90cca246e7bfc1efc072f8aad3</doaj_id><sourcerecordid>2632563889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3</originalsourceid><addsrcrecordid>eNp9ks-P1CAUx4nRuJtx_wEPhsSLlyrwWqAXE7PxxySbeNHEG6EUOkw6UKGdjf71MtN1dT2YECC8z_vCe3wRek7Ja0pAvsk1bUBUhLGKEEZJxR-hSyaauuJtC4_LHqCuGG--XaCrnPekUC1jEsRTdAFNyagbeYmWbTjaPPtBzz4MONnJzn72R4vnpEM2ZfJ6xAc9hBIwuKCHZSxwDLgMo0PQnc94yRbr0GMTh-DPUR_wZOM0Wnzr5x3OZud_xmmXbBF8hp44PWZ7dbdu0NcP779cf6puPn_cXr-7qUxTk7mqATg3tGkpGHCdMbxlkkquibBG9q7TxkHdslb2XDCqGQXb1UII3jltug42aLvq9lHv1ZT8QacfKmqvzgcxDUqnUtZoFae8711LjNGs5lZ0zlDrDBHMSa17KFpvV61p6Q62NzaUDo0PRB9Ggt-pIR6VlAKg_MkGvboTSPH7UpquDj4bO4462LhkxTiAFKKlrKAv_0H3cUmhtOpEsYaDlCdBtlImxZyTdfePoUSdTKJWk6hiEnU2ieIl6cXfZdyn_LZEAWAFcgmFwaY_d_9H9hc0EsuB</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2632563889</pqid></control><display><type>article</type><title>Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>Alma/SFX Local Collection</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Bidzinski, Karolina Kozak ; Lowe, Darby J. E. ; Sanches, Marcos ; Sorkhou, Maryam ; Boileau, Isabelle ; Kiang, Michael ; Blumberger, Daniel M. ; Remington, Gary ; Ma, Clement ; Castle, David J. ; Rabin, Rachel A. ; George, Tony P.</creator><creatorcontrib>Bidzinski, Karolina Kozak ; Lowe, Darby J. E. ; Sanches, Marcos ; Sorkhou, Maryam ; Boileau, Isabelle ; Kiang, Michael ; Blumberger, Daniel M. ; Remington, Gary ; Ma, Clement ; Castle, David J. ; Rabin, Rachel A. ; George, Tony P.</creatorcontrib><description>Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in the dorsolateral prefrontal cortex (DLPFC), a potential target for treatment development. We examined the effects of active versus sham high-frequency (20-Hz) repetitive transcranial magnetic stimulation (rTMS) on cannabis use in outpatients with schizophrenia and CUD. Secondary outcomes included cannabis craving/withdrawal, psychiatric symptoms, cognition and tobacco use. Twenty-four outpatients with schizophrenia and CUD were enrolled in a preliminary double-blind, sham-controlled randomized trial. Nineteen participants were randomized to receive active (
n
= 9) or sham (
n
= 10) rTMS (20-Hz) applied bilaterally to the DLPFC 5x/week for 4 weeks. Cannabis use was monitored twice weekly. A cognitive battery was administered pre- and post-treatment. rTMS was safe and well-tolerated with high treatment retention (~90%). Contrast estimates suggested greater reduction in self-reported cannabis use (measured in grams/day) in the active versus sham group (Estimate = 0.33,
p
= 0.21; Cohen’s
d
= 0.72), suggesting a clinically relevant effect of rTMS. A trend toward greater reduction in craving (Estimate = 3.92,
p
= 0.06), and significant reductions in PANSS positive (Estimate = 2.42,
p
= 0.02) and total (Estimate = 5.03,
p
= 0.02) symptom scores were found in the active versus sham group. Active rTMS also improved attention (Estimate = 6.58,
p
< 0.05), and suppressed increased tobacco use that was associated with cannabis reductions (Treatment x Time:
p
= 0.01). Our preliminary findings suggest that rTMS to the DLPFC is safe and potentially efficacious for treating CUD in schizophrenia.</description><identifier>ISSN: 2334-265X</identifier><identifier>ISSN: 2754-6993</identifier><identifier>EISSN: 2754-6993</identifier><identifier>EISSN: 2334-265X</identifier><identifier>DOI: 10.1038/s41537-022-00210-6</identifier><identifier>PMID: 35210458</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/378/1595/1636 ; 692/699/476/1799 ; Cognitive Psychology ; Marijuana ; Medicine ; Medicine & Public Health ; Neurology ; Neurosciences ; Psychiatry ; Schizophrenia ; Transcranial magnetic stimulation</subject><ispartof>NPJ schizophrenia, 2022-02, Vol.8 (1), p.2-2, Article 2</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3</citedby><cites>FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3</cites><orcidid>0000-0003-1645-9767 ; 0000-0001-9075-1761</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2632563889/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2632563889?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,44569,53770,53772,74873</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35210458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bidzinski, Karolina Kozak</creatorcontrib><creatorcontrib>Lowe, Darby J. E.</creatorcontrib><creatorcontrib>Sanches, Marcos</creatorcontrib><creatorcontrib>Sorkhou, Maryam</creatorcontrib><creatorcontrib>Boileau, Isabelle</creatorcontrib><creatorcontrib>Kiang, Michael</creatorcontrib><creatorcontrib>Blumberger, Daniel M.</creatorcontrib><creatorcontrib>Remington, Gary</creatorcontrib><creatorcontrib>Ma, Clement</creatorcontrib><creatorcontrib>Castle, David J.</creatorcontrib><creatorcontrib>Rabin, Rachel A.</creatorcontrib><creatorcontrib>George, Tony P.</creatorcontrib><title>Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia</title><title>NPJ schizophrenia</title><addtitle>Schizophr</addtitle><addtitle>NPJ Schizophr</addtitle><description>Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in the dorsolateral prefrontal cortex (DLPFC), a potential target for treatment development. We examined the effects of active versus sham high-frequency (20-Hz) repetitive transcranial magnetic stimulation (rTMS) on cannabis use in outpatients with schizophrenia and CUD. Secondary outcomes included cannabis craving/withdrawal, psychiatric symptoms, cognition and tobacco use. Twenty-four outpatients with schizophrenia and CUD were enrolled in a preliminary double-blind, sham-controlled randomized trial. Nineteen participants were randomized to receive active (
n
= 9) or sham (
n
= 10) rTMS (20-Hz) applied bilaterally to the DLPFC 5x/week for 4 weeks. Cannabis use was monitored twice weekly. A cognitive battery was administered pre- and post-treatment. rTMS was safe and well-tolerated with high treatment retention (~90%). Contrast estimates suggested greater reduction in self-reported cannabis use (measured in grams/day) in the active versus sham group (Estimate = 0.33,
p
= 0.21; Cohen’s
d
= 0.72), suggesting a clinically relevant effect of rTMS. A trend toward greater reduction in craving (Estimate = 3.92,
p
= 0.06), and significant reductions in PANSS positive (Estimate = 2.42,
p
= 0.02) and total (Estimate = 5.03,
p
= 0.02) symptom scores were found in the active versus sham group. Active rTMS also improved attention (Estimate = 6.58,
p
< 0.05), and suppressed increased tobacco use that was associated with cannabis reductions (Treatment x Time:
p
= 0.01). Our preliminary findings suggest that rTMS to the DLPFC is safe and potentially efficacious for treating CUD in schizophrenia.</description><subject>631/378/1595/1636</subject><subject>692/699/476/1799</subject><subject>Cognitive Psychology</subject><subject>Marijuana</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Psychiatry</subject><subject>Schizophrenia</subject><subject>Transcranial magnetic stimulation</subject><issn>2334-265X</issn><issn>2754-6993</issn><issn>2754-6993</issn><issn>2334-265X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks-P1CAUx4nRuJtx_wEPhsSLlyrwWqAXE7PxxySbeNHEG6EUOkw6UKGdjf71MtN1dT2YECC8z_vCe3wRek7Ja0pAvsk1bUBUhLGKEEZJxR-hSyaauuJtC4_LHqCuGG--XaCrnPekUC1jEsRTdAFNyagbeYmWbTjaPPtBzz4MONnJzn72R4vnpEM2ZfJ6xAc9hBIwuKCHZSxwDLgMo0PQnc94yRbr0GMTh-DPUR_wZOM0Wnzr5x3OZud_xmmXbBF8hp44PWZ7dbdu0NcP779cf6puPn_cXr-7qUxTk7mqATg3tGkpGHCdMbxlkkquibBG9q7TxkHdslb2XDCqGQXb1UII3jltug42aLvq9lHv1ZT8QacfKmqvzgcxDUqnUtZoFae8711LjNGs5lZ0zlDrDBHMSa17KFpvV61p6Q62NzaUDo0PRB9Ggt-pIR6VlAKg_MkGvboTSPH7UpquDj4bO4462LhkxTiAFKKlrKAv_0H3cUmhtOpEsYaDlCdBtlImxZyTdfePoUSdTKJWk6hiEnU2ieIl6cXfZdyn_LZEAWAFcgmFwaY_d_9H9hc0EsuB</recordid><startdate>20220224</startdate><enddate>20220224</enddate><creator>Bidzinski, Karolina Kozak</creator><creator>Lowe, Darby J. E.</creator><creator>Sanches, Marcos</creator><creator>Sorkhou, Maryam</creator><creator>Boileau, Isabelle</creator><creator>Kiang, Michael</creator><creator>Blumberger, Daniel M.</creator><creator>Remington, Gary</creator><creator>Ma, Clement</creator><creator>Castle, David J.</creator><creator>Rabin, Rachel A.</creator><creator>George, Tony P.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1645-9767</orcidid><orcidid>https://orcid.org/0000-0001-9075-1761</orcidid></search><sort><creationdate>20220224</creationdate><title>Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia</title><author>Bidzinski, Karolina Kozak ; Lowe, Darby J. E. ; Sanches, Marcos ; Sorkhou, Maryam ; Boileau, Isabelle ; Kiang, Michael ; Blumberger, Daniel M. ; Remington, Gary ; Ma, Clement ; Castle, David J. ; Rabin, Rachel A. ; George, Tony P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/378/1595/1636</topic><topic>692/699/476/1799</topic><topic>Cognitive Psychology</topic><topic>Marijuana</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Psychiatry</topic><topic>Schizophrenia</topic><topic>Transcranial magnetic stimulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bidzinski, Karolina Kozak</creatorcontrib><creatorcontrib>Lowe, Darby J. E.</creatorcontrib><creatorcontrib>Sanches, Marcos</creatorcontrib><creatorcontrib>Sorkhou, Maryam</creatorcontrib><creatorcontrib>Boileau, Isabelle</creatorcontrib><creatorcontrib>Kiang, Michael</creatorcontrib><creatorcontrib>Blumberger, Daniel M.</creatorcontrib><creatorcontrib>Remington, Gary</creatorcontrib><creatorcontrib>Ma, Clement</creatorcontrib><creatorcontrib>Castle, David J.</creatorcontrib><creatorcontrib>Rabin, Rachel A.</creatorcontrib><creatorcontrib>George, Tony P.</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>NPJ schizophrenia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bidzinski, Karolina Kozak</au><au>Lowe, Darby J. E.</au><au>Sanches, Marcos</au><au>Sorkhou, Maryam</au><au>Boileau, Isabelle</au><au>Kiang, Michael</au><au>Blumberger, Daniel M.</au><au>Remington, Gary</au><au>Ma, Clement</au><au>Castle, David J.</au><au>Rabin, Rachel A.</au><au>George, Tony P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia</atitle><jtitle>NPJ schizophrenia</jtitle><stitle>Schizophr</stitle><addtitle>NPJ Schizophr</addtitle><date>2022-02-24</date><risdate>2022</risdate><volume>8</volume><issue>1</issue><spage>2</spage><epage>2</epage><pages>2-2</pages><artnum>2</artnum><issn>2334-265X</issn><issn>2754-6993</issn><eissn>2754-6993</eissn><eissn>2334-265X</eissn><abstract>Cannabis use disorder (CUD) occurs at high rates in schizophrenia, which negatively impacts its clinical prognosis. These patients have greater difficulty quitting cannabis which may reflect putative deficits in the dorsolateral prefrontal cortex (DLPFC), a potential target for treatment development. We examined the effects of active versus sham high-frequency (20-Hz) repetitive transcranial magnetic stimulation (rTMS) on cannabis use in outpatients with schizophrenia and CUD. Secondary outcomes included cannabis craving/withdrawal, psychiatric symptoms, cognition and tobacco use. Twenty-four outpatients with schizophrenia and CUD were enrolled in a preliminary double-blind, sham-controlled randomized trial. Nineteen participants were randomized to receive active (
n
= 9) or sham (
n
= 10) rTMS (20-Hz) applied bilaterally to the DLPFC 5x/week for 4 weeks. Cannabis use was monitored twice weekly. A cognitive battery was administered pre- and post-treatment. rTMS was safe and well-tolerated with high treatment retention (~90%). Contrast estimates suggested greater reduction in self-reported cannabis use (measured in grams/day) in the active versus sham group (Estimate = 0.33,
p
= 0.21; Cohen’s
d
= 0.72), suggesting a clinically relevant effect of rTMS. A trend toward greater reduction in craving (Estimate = 3.92,
p
= 0.06), and significant reductions in PANSS positive (Estimate = 2.42,
p
= 0.02) and total (Estimate = 5.03,
p
= 0.02) symptom scores were found in the active versus sham group. Active rTMS also improved attention (Estimate = 6.58,
p
< 0.05), and suppressed increased tobacco use that was associated with cannabis reductions (Treatment x Time:
p
= 0.01). Our preliminary findings suggest that rTMS to the DLPFC is safe and potentially efficacious for treating CUD in schizophrenia.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>35210458</pmid><doi>10.1038/s41537-022-00210-6</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1645-9767</orcidid><orcidid>https://orcid.org/0000-0001-9075-1761</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2334-265X |
| ispartof | NPJ schizophrenia, 2022-02, Vol.8 (1), p.2-2, Article 2 |
| issn | 2334-265X 2754-6993 2754-6993 2334-265X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_616ddf90cca246e7bfc1efc072f8aad3 |
| source | PubMed (Medline); Publicly Available Content Database; Alma/SFX Local Collection; Springer Nature - nature.com Journals - Fully Open Access |
| subjects | 631/378/1595/1636 692/699/476/1799 Cognitive Psychology Marijuana Medicine Medicine & Public Health Neurology Neurosciences Psychiatry Schizophrenia Transcranial magnetic stimulation |
| title | Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigating%20repetitive%20transcranial%20magnetic%20stimulation%20on%20cannabis%20use%20and%20cognition%20in%20people%20with%20schizophrenia&rft.jtitle=NPJ%20schizophrenia&rft.au=Bidzinski,%20Karolina%20Kozak&rft.date=2022-02-24&rft.volume=8&rft.issue=1&rft.spage=2&rft.epage=2&rft.pages=2-2&rft.artnum=2&rft.issn=2334-265X&rft.eissn=2754-6993&rft_id=info:doi/10.1038/s41537-022-00210-6&rft_dat=%3Cproquest_doaj_%3E2632563889%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-43366c15913c3fbcc6928186a07ec8dfbacf349298d6721a213eb47776bfacbb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2632563889&rft_id=info:pmid/35210458&rfr_iscdi=true |